# US Opioids Market > US Opioids Market Research Report: Size, Share, Trend Analysis By Types (Natural Opioids, Semi-Synthetic Opioids, Fully Synthetic Opioids), By Applications (Pain Management, Anesthesia, Cough Suppression, Diarrhea Treatment), By Route of Administration (Oral, Injectable, Transdermal, Topical) and By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) - Growth Outlook & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 2.44% - **2024:** $ 13.2 Billion - **2025:** $ 13.52 Billion - **2035:** $ 17.2 Billion - **Key Players:** Purdue Pharma (US), Johnson & Johnson (US), Teva Pharmaceutical Industries (IL), Mylan N.V. (US), Endo International (IE), Mallinckrodt Pharmaceuticals (IE), Amgen Inc. (US), Boehringer Ingelheim (DE) **Report ID:** MRFR/HC/13077-HCR · **Pages:** 100 · **Author:** Rahul Gotadki & Garvit Vyas · **Last Updated:** April 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/us-opioids-market-14604 --- ## Market Summary ## **US Opioids Market Overview** **As per MRFR analysis, the US Opioids Market Size was estimated at 8.1 (USD Billion) in 2023. The US Opioids Market Industry is expected to grow from 9 (USD Billion) in 2024 to 12 (USD Billion) by 2035. The US Opioids Market CAGR (growth rate) is expected to be around 2.65% during the forecast period (2025 - 2035).** ### **Key US Opioids Market Trends Highlighted** This regulatory shift compels pharmaceutical companies to innovate with safer alternatives, encouraging the development of non-opioid pain management therapies. Opportunities to be explored include the growing demand for addiction treatment services and the expansion of telemedicine. With the rise in opioid dependency, there is a pressing need for effective treatment programs. Telemedicine has gained traction, allowing patients to seek help more conveniently and confidentially, thereby broadening access to treatment options. Moreover, ongoing research into non-addictive pain relief methods presents a notable opportunity for businesses to invest in new product development and novel therapies. Recent trends indicate a significant focus on harm reduction strategies as part of state and federal initiatives, including the distribution of naloxone, an opioid overdose reversal drug. Such measures reflect a shift in public health priorities towards mitigation rather than solely relying on prescription strategies. Additionally, there is increasing collaboration between healthcare providers, policymakers, and communities to create comprehensive approaches for managing pain while minimizing the risk of addiction. The overall landscape of the US [Opioids](../../../reports/opioids-market-7626) Market is evolving, highlighting the necessity for innovative solutions and cohesive strategies in tackling the intricate issues surrounding opioid use and dependence. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ## **US Opioids Market Drivers** ### **Increase in Chronic Pain Management Needs** The rising prevalence of chronic pain conditions among the United States population significantly drives the US Opioids Market Industry. According to the American Academy of Pain Medicine, approximately 100 million adults in the U.S. suffer from chronic pain. This translates to roughly one-third of the adult population. Chronic pain not only affects daily activities but also leads to increased healthcare costs. As a result, healthcare providers are often prescribed opioid medications as a first-line treatment option to help manage this pain. This surge in demand for effective pain management therapies is expected to contribute to the growth of the US Opioids Market, as seen from the changes in prescription patterns guided by the Centers for Disease Control and Prevention's prescription guidelines. Furthermore, as the Baby Boomer generation continues to age, the need for pain management solutions is anticipated to rise, bolstering market prospects for opioids. ### **Government Initiatives for Opioid Prescriptions** In response to the ongoing opioid crisis, various government initiatives to regulate and monitor opioid prescriptions have been introduced. The U.S. Department of Health and Human Services has set forth programs aimed at improving the safe prescribing of opioids, thereby indirectly promoting their use under monitored conditions. These initiatives include the establishment of Prescription Drug Monitoring Programs (PDMPs) which help track prescription drug use across states. According to the National Institute on Drug Abuse, effective monitoring has led to a significant decrease in the misuse of prescription opioids by approximately 30% in certain regions, while still allowing for legitimate pain management needs. As these efforts continue, the balance between regulation and accessibility can further stabilize and potentially grow the US Opioids Market Industry. ### **Technological Advancements in Drug Development** Continuous advancements in pharmaceuticals and drug delivery systems are poised to enhance the US Opioids Market Industry significantly. Innovations such as abuse-deterrent formulations and extended-release delivery systems are emerging trends aimed at addressing safety concerns while still providing effective pain relief. According to the Food and Drug Administration (FDA), over 60 abuse-deterrent formulations have been approved since their introduction in 2010, which helps address the misuse and addiction issues associated with traditional opioids. This innovation lays the foundation for a more responsible opioid prescription environment while meeting the therapeutic needs of patients. The advancement in Research and Development (R&D) within pharmaceutical companies ensures that the market evolves to mitigate risks while enhancing the support for chronic pain patients. ## **US Opioids Market Segment Insights** ### **Opioids Market Type Insights** They have emerged as preferred options in treating chronic pain conditions, showcasing their importance in managing patient outcomes. Fully Synthetic Opioids, on the other hand, are entirely man-made, providing unique benefits such as the ability to tailor efficacy and safety profiles, making them vital in acute pain management and palliative care. Each of these categories presents unique growth drivers, such as rising prevalence of chronic pain and advancements in pharmaceutical formulations. However, the US faces challenges of opioid misuse and regulatory scrutiny, pushing the industry to explore safer and more effective alternatives. The segmentation of the US Opioids Market highlights a complex landscape where each Type contributes to overall therapeutic strategies, reflecting broader healthcare trends. Together, they form a crucial framework for understanding drug prescriptions and public health responses in a country grappling with opioid-related issues, enhancing the US Opioids Market dynamics. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ### **Opioids Market Application Insights** Cough Suppression is essential, especially in pediatric patients, to manage severe coughing associated with respiratory illnesses. Diarrhea Treatment represents another significant application, as certain opioids are employed to control severe diarrhea by slowing intestinal movement. The US Opioids Market statistics reveal that increased demand for efficient pain relief and demand within these applications drive market growth. Furthermore, rising instances of chronic pain and surgical procedures in the US underline the ongoing relevance of opioids in healthcare settings, providing growth opportunities for the industry. However, addressing the challenges of opioid misuse and dependency remains a critical focus as the market evolves. ### **Opioids Market Route of Administration Insights** Topical formulations are gaining traction for localized pain relief, minimizing systemic side effects, particularly beneficial for populations sensitive to opioids' systemic impact. The growing emphasis on personalized medicine and chronic pain management strategies is shaping the preferences for these routes, driving continuous innovations and adaptations in formulations, safety, and efficacy. Moreover, regulatory considerations and evolving clinical guidelines are influencing market access and utilization patterns across these routes, reflecting an ongoing response to the opioid crisis in the US. Understanding these dynamics is essential for stakeholders aiming to navigate the complexities of the Opioids Market effectively. ### **Opioids Market Distribution Channel Insights** Retail Pharmacies dominate the distribution landscape due to their widespread presence and the convenience they offer to consumers seeking prescription medications. Online Pharmacies have gained traction recently, driven by technological advancements and the increasing preference for home delivery services, allowing patients to access medications without stepping out of their homes. The growth of the US Opioids Market is influenced by factors such as the rising incidence of chronic pain conditions, regulatory changes, and a focus on better patient management practices. However, challenges like opioid abuse and strict regulations also shape the dynamics of this segment. Overall, understanding the nuances of these distribution channels is essential for grasping the broader US Opioids Market landscape as each plays a vital role in addressing patient needs while navigating the complexities of opioid distribution. ## **US Opioids Market Key Players and Competitive Insights** The competitive landscape of the US Opioids Market is characterized by a complex interplay of regulatory pressures, emerging therapeutic needs, and evolving consumer perceptions of pain management. With the increasing scrutiny on opioid prescriptions amid the opioid crisis, companies operating within this sphere are compelled to adapt their strategies to maintain their market share while prioritizing patient safety. Market players have been compelled to innovate by focusing on the development of newer formulations, abuse-deterrent technologies, and alternative therapies that cater to both chronic and acute pain management. Furthermore, collaborations and partnerships within the pharmaceutical industry have become increasingly vital as companies seek to leverage their strengths and enhance their competitive positioning in an environment marked by high competition and rapid changes. ### **AstraZeneca** AstraZeneca has made significant strides in the US Opioids Market through its impactful approach to pain management. The company has focused on developing innovative therapies that address unmet medical needs while ensuring compliance with evolving regulatory standards. AstraZeneca's strength lies in its strong research and development capabilities, allowing for the continuous introduction of new products that enhance its portfolio in the opioids segment. Additionally, its existing relationships with healthcare providers and a deep understanding of market dynamics have enabled AstraZeneca to establish a robust presence in the pain management sector. By maintaining a patient-centered focus and emphasizing responsible prescribing practices, AstraZeneca aims to contribute positively to pain alleviation while navigating the complexities of the opioid landscape. ### **BristolMyers Squibb** BristolMyers Squibb has positioned itself as a formidable player in the US Opioids Market by offering a range of products that cater to various pain management needs. The company develops and markets opioids that are recognized for their efficacy in treating severe pain, thus contributing to BristolMyers Squibb's strong reputation within the field. Their portfolio is bolstered by their commitment to research and innovation, which has led to the introduction of advanced formulations and delivery methods. BristolMyers Squibb's strengths also include strategic mergers and acquisitions that have allowed for expansion in its product offerings and capabilities in the therapeutics space. The company's effective marketing strategies, combined with its emphasis on safety and efficacy, reinforce its market position even in a challenging regulatory environment. As the opioid crisis poses ongoing challenges to the industry, BristolMyers Squibb continues to navigate this landscape while prioritizing the needs of patients and healthcare providers. ### **Key Companies in the US Opioids Market Include** ## **US Opioids Market Industry Developments** In recent months, the US Opioids Market has seen significant developments, particularly regarding litigation and regulatory changes. Purdue Pharma continues to be a focal point as it works through its bankruptcy plan and settlement over its role in the opioid crisis, proposing a payout to victims and states. AstraZeneca, Bristol-Myers Squibb, and Johnson and Johnson have also faced scrutiny, with ongoing federal and state lawsuits concerning their marketing practices for opioid medications. The market has been influenced by legislative actions aimed at curbing opioid prescriptions and improving addiction treatment access. In terms of mergers and acquisitions, there have been no prominent deals reported among the specified companies within the last few months. Nevertheless, some companies like Mallinckrodt have experienced financial challenges leading to asset sales, while others like Teva Pharmaceuticals are navigating market shifts prompted by increased competition and regulatory pressures. Over the past few years, the market has faced growing pressures with the comprehensive 2020 opioid litigation settlements, impacting the strategies of companies in the sector. The evolving healthcare landscape emphasizes the importance of responsible pain management and addiction recovery initiatives across the US. ## **US Opioids Market Segmentation Insights** ### **Opioids Market Type Outlook** ### **Opioids Market Application Outlook** ### **Opioids Market Route of Administration Outlook** ### **Opioids Market Distribution Channel Outlook** ## Market Drivers ### Rising Pain Management Needs The increasing prevalence of chronic pain conditions in the US is a primary driver for the opioids market. According to recent data, approximately 20% of adults in the US experience chronic pain, leading to a heightened demand for effective pain management solutions. This trend is likely to continue as the aging population grows, with projections indicating that by 2030, nearly 20% of the US population will be over 65 years old. As healthcare providers seek to address these needs, the opioids market is expected to expand, with a focus on balancing efficacy and safety in pain management. The ongoing evolution of treatment protocols may further influence prescribing practices, thereby impacting market dynamics. ### Evolving Regulatory Landscape The regulatory environment surrounding the opioids market is undergoing significant changes, which could have profound implications for market dynamics. Recent legislative efforts aim to address the opioid crisis by implementing stricter prescribing guidelines and enhancing monitoring systems. For instance, the introduction of prescription drug monitoring programs (PDMPs) has been shown to reduce opioid prescriptions by approximately 10-15% in states that have adopted them. These regulations may lead to a shift in prescribing patterns, with healthcare providers increasingly opting for alternative pain management therapies. While these measures are intended to curb misuse, they may also create challenges for patients requiring legitimate pain relief, thereby influencing the overall market landscape. ### Increased Focus on Addiction Treatment The growing recognition of opioid addiction as a public health crisis is driving demand for comprehensive treatment options within the opioids market. With an estimated 2 million individuals in the US suffering from opioid use disorder, there is an urgent need for effective addiction treatment programs. This has led to increased funding for rehabilitation services and the development of medications aimed at treating addiction, such as buprenorphine and methadone. As healthcare systems prioritize addiction treatment, the market may see a shift in focus from solely pain management to a more holistic approach that includes addiction recovery. This dual focus could reshape the landscape of the opioids market, influencing both prescribing practices and patient outcomes. ### Growing Demand for Personalized Medicine The trend towards personalized medicine is emerging as a key driver in the opioids market. As healthcare providers increasingly recognize that patients respond differently to medications, there is a growing emphasis on tailoring pain management strategies to individual needs. Genetic testing and biomarker identification are becoming more prevalent, allowing for more precise prescribing of opioids and alternative therapies. This shift towards personalized approaches may enhance treatment efficacy and minimize the risk of adverse effects. As the healthcare industry continues to evolve, the opioids market is likely to adapt to these changes, potentially leading to more effective pain management solutions that align with the principles of personalized medicine. ### Advancements in Pain Management Technologies Technological innovations in pain management are emerging as a significant driver for the opioids market. The development of new drug delivery systems, such as transdermal patches and implantable devices, offers potential alternatives to traditional oral opioids. These advancements may enhance patient compliance and reduce the risk of misuse. Furthermore, the integration of digital health technologies, including telemedicine and mobile health applications, is facilitating better patient monitoring and management of pain conditions. As these technologies gain traction, they could reshape the treatment landscape, potentially impacting the demand for traditional opioids. The opioids market may thus experience a transformation as healthcare providers adopt these innovative solutions. ## Future Outlook The [Opioids Market](https://www.marketresearchfuture.com/reports/opioids-market-7626) is projected to grow at a 2.44% CAGR from 2025 to 2035, driven by increasing demand for pain management and innovative delivery systems. **New opportunities:** - Development of personalized opioid formulations for chronic pain management. - - Expansion of telehealth services for opioid prescriptions and monitoring. - Investment in advanced analytics for opioid prescription optimization. By 2035, the opioids market is expected to stabilize with sustainable growth and enhanced regulatory compliance. ## Segment Insights ### By Type: Semi-synthetic Opioids (Largest) vs. Fully Synthetic Opioids (Fastest-Growing) The US [opioids market](https://www.marketresearchfuture.com/reports/opioids-market-7626) demonstrates a diverse distribution across different types of opioids, where semi-synthetic opioids hold the largest market share. This segment is characterized by a substantial volume of prescriptions and a well-established presence in both pain management and chronic pain therapies. Natural opioids and opioid derivatives form the other segments, yet they have observed comparatively lower shares due to increasing regulatory scrutiny and shifting prescribing practices. Growth trends in the US opioids market are significantly impacted by the rising incidence of chronic pain conditions leading to a consistent demand for opioids. Semi-synthetic opioids are growing due to their enhanced efficacy and formulation advancements, while fully synthetic opioids are emerging as the fastest-growing segment, driven by innovations in pain management solutions and the potential for fewer side effects. This trend indicates a shift towards more controlled medication in response to the opioid crisis. Semi-synthetic Opioids (Dominant) vs. Fully Synthetic Opioids (Emerging) Semi-synthetic opioids are predominantly utilized in clinical settings for their effectiveness and reliability in pain relief, making them a dominant segment in the US opioids market. This category includes well-known medications like oxycodone and hydrocodone, which are frequently prescribed. In contrast, fully synthetic opioids, such as fentanyl, present an emerging opportunity within the market due to their high potency and rapid onset of action, appealing to specific patient needs. Despite concerns regarding their abuse potential, advances in formulation and delivery methods are positioning fully synthetic opioids as a relevant and promising option, offering less potential for dependency compared to their semi-synthetic counterparts. ### By Route of Administration: Oral (Largest) vs. Injectable (Fastest-Growing) The market share distribution within the route of administration segment reveals that oral opioids hold the largest share, appealing to patients due to their convenience and ease of use. Injectable forms, while smaller in comparison, are gaining traction in acute care settings and among healthcare providers who require rapid pain relief. Growth trends indicate an increasing preference for injectable opioids due to their effectiveness and faster onset of action, particularly in surgical procedures. Additionally, innovations in transdermal and nasal routes are enhancing patient compliance. Increased awareness of pain management options is further driving the growth, along with the rise in chronic pain cases requiring effective therapeutic solutions. Oral (Dominant) vs. Injectable (Emerging) Oral opioids dominate the route of administration segment, favored for their user-friendliness and ability to be administered at home, leading to significant patient adherence and satisfaction. On the other hand, the injectable category is emerging due to its effectiveness in delivering immediate relief in various clinical situations, especially in hospitals. This segment is undergoing rapid development with advancements in formulation technology and delivery methods, thus making them more appealing for inpatient therapy. Both segments showcase unique advantages, with oral opioids being preferable for long-term use, while injectables cater to acute medical needs. ### By Therapeutic Application: Pain Management (Largest) vs. Cough Suppression (Fastest-Growing) In the US opioids market, the market share distribution among therapeutic applications reveals Pain Management as the dominant segment, accounting for the largest share of revenue. Cough Suppression, on the other hand, is gaining traction and is recognized as the fastest-growing segment, driven by increasing demand for effective cough remedies tied to various health conditions. Other segments such as Diarrhea Treatment and Anesthesia also contribute, although at comparatively smaller shares. The growth trends within these segments are driven by an increasing prevalence of chronic pain conditions and respiratory issues requiring treatment. Innovations in formulation and delivery methods are enhancing the efficacy of opioids in Pain Management and Cough Suppression. Furthermore, rising awareness regarding opioid medications and their applications is leading to a significant uptick in prescriptions, particularly in the fastest-growing segment, which reflects evolving consumer needs. Pain Management (Dominant) vs. Cough Suppression (Emerging) Pain Management remains the dominant therapeutic application in the US opioids market, primarily due to the high prevalence of chronic pain conditions among the population. It encompasses a broad range of opioid medications designed to alleviate pain effectively, making it a preferential choice for healthcare professionals. Conversely, Cough Suppression is emerging rapidly, driven by a surge in demand for reliable cough remedies that are often combined with other medications to enhance patient care. This segment's growth is supported by new drug approvals and innovative combinations that improve patient outcomes and satisfaction. Together, these segments illustrate the diversity in therapeutic applications and the evolving landscape of the US opioids market. ### By Patient Population: Chronic Pain Patients (Largest) vs. Cancer Patients (Fastest-Growing) In the US opioids market, the patient population segment is primarily dominated by chronic pain patients, who account for a significant portion of opioid prescriptions due to the widespread prevalence of chronic pain conditions. Following them are postoperative pain patients, cancer patients, and palliative care patients, each holding a crucial position in the market. Cancer patients, while smaller in number compared to chronic pain patients, exhibit growing demands for opioids, particularly as treatment modalities evolve and the focus shifts toward pain management in oncology. Growth trends within the patient population segment reveal an increasing reliance on opioids among cancer patients due to advancements in cancer treatment and the need for effective pain relief. Postoperative pain management continues to drive prescriptions, while chronic pain remains a persistent challenge. Additionally, an aging population and rising incidence of chronic illnesses are propelling demand in this sector, contributing to an evolving landscape defined by both challenges and opportunities for stakeholders in the US opioids market. Chronic Pain Patients (Dominant) vs. Cancer Patients (Emerging) Chronic pain patients represent the dominant segment in the US opioids market, characterized by a high volume of prescriptions driven by various chronic conditions such as arthritis, fibromyalgia, and lower back pain. This segment has established a solid market foothold due to the long-term need for pain management solutions. Detailed treatment plans often include a range of opioids tailored to individual patient needs. Meanwhile, cancer patients are emerging as a significant segment, reflecting the rising awareness around cancer pain management and the therapeutic roles of opioids in treating pain associated with malignant conditions. This growth is bolstered by improved clinical guidelines and patient-focused approaches, enhancing the understanding and effective management of pain in oncology. ## Competitive Benchmarking The opioids market exhibits a complex competitive landscape characterized by a mix of established players and emerging entities. Key growth drivers include the increasing prevalence of chronic pain conditions and the ongoing demand for effective pain management solutions. Major companies such as Purdue Pharma (US), Johnson & Johnson (US), and Teva Pharmaceutical Industries (IL) are strategically positioned to leverage their extensive portfolios and research capabilities. Purdue Pharma (US) has focused on reformulating its products to enhance safety profiles, while Johnson & Johnson (US) emphasizes innovation through partnerships aimed at developing non-opioid alternatives. Teva Pharmaceutical Industries (IL) continues to expand its generics segment, which plays a crucial role in maintaining competitive pricing and accessibility in the market.The business tactics employed by these companies reflect a concerted effort to optimize supply chains and localize manufacturing processes. The market structure appears moderately fragmented, with a few dominant players exerting considerable influence. This fragmentation allows for niche players to emerge, yet the collective strength of the key players shapes pricing strategies and market access, creating a competitive environment that is both dynamic and challenging. In October Purdue Pharma (US) announced a strategic partnership with a biotechnology firm to develop a new class of pain management therapies. This collaboration is significant as it indicates Purdue's commitment to diversifying its product offerings and addressing the growing demand for safer pain relief options. The partnership may also enhance Purdue's research capabilities, positioning the company favorably in a market increasingly focused on innovation. In September Johnson & Johnson (US) launched a digital health platform aimed at improving patient adherence to prescribed pain management regimens. This initiative underscores the company's focus on integrating technology into its product offerings, potentially enhancing patient outcomes and fostering brand loyalty. By leveraging digital tools, Johnson & Johnson (US) may effectively differentiate itself in a crowded market. In August Teva Pharmaceutical Industries (IL) expanded its manufacturing capabilities in the US, investing approximately $50 million in a new facility. This move is likely to bolster Teva's supply chain efficiency and reduce lead times for product delivery. Such investments reflect a broader trend among key players to enhance operational resilience and responsiveness to market demands. As of November the competitive trends in the opioids market are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence (AI) in drug development and patient management. Strategic alliances are becoming more prevalent, enabling companies to pool resources and expertise to navigate regulatory challenges and innovate effectively. Looking ahead, competitive differentiation is expected to evolve, with a shift from price-based competition towards a focus on innovation, technological advancements, and supply chain reliability. This transition may ultimately reshape the market dynamics, fostering a landscape where companies that prioritize research and development, alongside sustainable practices, are more likely to thrive. ## Recent News & Developments In recent months, the US Opioids Market has seen significant developments, particularly regarding litigation and regulatory changes. Purdue Pharma continues to be a focal point as it works through its bankruptcy plan and settlement over its role in the opioid crisis, proposing a payout to victims and states. AstraZeneca, Bristol-Myers Squibb, and Johnson and Johnson have also faced scrutiny, with ongoing federal and state lawsuits concerning their marketing practices for opioid medications. The market has been influenced by legislative actions aimed at curbing opioid prescriptions and improving addiction treatment access. In terms of mergers and acquisitions, there have been no prominent deals reported among the specified companies within the last few months. Nevertheless, some companies like Mallinckrodt have experienced financial challenges leading to asset sales, while others like Teva Pharmaceuticals are navigating market shifts prompted by increased competition and regulatory pressures. Over the past few years, the market has faced growing pressures with the comprehensive 2020 opioid litigation settlements, impacting the strategies of companies in the sector. The evolving healthcare landscape emphasizes the importance of responsible pain management and addiction recovery initiatives across the US. ## Report Scope | MARKET SIZE 2024 | 13.2(USD Billion) | | --- | --- | | MARKET SIZE 2025 | 13.52(USD Billion) | | MARKET SIZE 2035 | 17.2(USD Billion) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 2.44% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Billion | | Key Companies Profiled | Purdue Pharma (US), Johnson & Johnson (US), Teva Pharmaceutical Industries (IL), Mylan N.V. (US), Endo International (IE), Mallinckrodt Pharmaceuticals (IE), Amgen Inc. (US), Boehringer Ingelheim (DE) | | Segments Covered | Type, Route of Administration, Therapeutic Application, Patient Population | | Key Market Opportunities | Emerging therapies targeting pain management and addiction recovery present growth opportunities in the opioids market. | | Key Market Dynamics | Regulatory scrutiny intensifies, driving innovation and reshaping competitive dynamics in the opioids market. | | Countries Covered | US | ## Frequently Asked Questions **Q: What was the overall valuation of the US opioids market in 2024?** A: The overall market valuation was $13.2 Billion in 2024. **Q: What is the projected market valuation for the US opioids market by 2035?** A: The projected valuation for 2035 is $17.2 Billion. **Q: What is the expected CAGR for the US opioids market during the forecast period 2025 - 2035?** A: The expected CAGR for the market during this period is 2.44%. **Q: Which companies are considered key players in the US opioids market?** A: Key players include Purdue Pharma, Johnson & Johnson, Teva Pharmaceutical Industries, Mylan N.V., Endo International, Mallinckrodt Pharmaceuticals, Amgen Inc., and Boehringer Ingelheim. **Q: What are the segment valuations for Natural Opioids in 2025?** A: The segment valuation for Natural Opioids is projected to be between $4.5 Billion and $5.5 Billion in 2025. **Q: How does the valuation of Semi-synthetic Opioids change from 2024 to 2025?** A: The valuation for Semi-synthetic Opioids is expected to increase from $4.0 Billion in 2024 to $5.0 Billion in 2025. **Q: What is the projected valuation for Pain Management applications in 2025?** A: The projected valuation for Pain Management applications is between $8.0 Billion and $10.0 Billion in 2025. **Q: What is the expected market size for Chronic Pain Patients in 2025?** A: The expected market size for Chronic Pain Patients is projected to be between $5.0 Billion and $6.5 Billion in 2025. **Q: What are the projected valuations for the different routes of administration in 2025?** A: In 2025, Oral is projected at $6.5 Billion, Injectable at $3.8 Billion, Transdermal at $2.5 Billion, Rectal at $1.2 Billion, and Nasal at $3.2 Billion. **Q: What is the expected growth trend for the US opioids market in the coming years?** A: The market appears to be on a growth trend, with a projected increase in valuation from $13.2 Billion in 2024 to $17.2 Billion by 2035. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-opioids-market-14604*